Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
pharmaphorum20h
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
and have been reaping the rewards of supplying versions of Novo Nordisk's obesity drug Wegovy and Ozempic for diabetes, which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
US Woman Sheds 75 kg With ‘Miracle’ Ozempic Drug But She Now Faces New Challenges
While the transformation has contributed to Amy’s regained self-esteem, she has also been sharing her experience to help ...
‘Weight-loss drugs seemed good alternative but...’: How Ozempic led to vision blindness disaster - survivor recounts
A US resident lost around 40 kilos using a weight-loss drug but developed vision problems, to be ultimately diagnosed with ...